Strides Pharma Science Sustainability Profile
Strides Pharma Science Limited, commonly referred to as Strides, is a prominent player in the global pharmaceutical industry, headquartered in Bengaluru, India. Founded in 1990, the company has established a strong presence in various operational regions, including North America, Europe, and Africa. Strides focuses on the development, manufacturing, and marketing of a diverse range of pharmaceutical products, particularly in the areas of generic medications, complex generics, and over-the-counter (OTC) products. With a commitment to quality and innovation, Strides has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust pipeline of products. The company is recognised for its unique offerings in the injectable and oral dosage forms, positioning itself as a trusted partner in the healthcare sector. Strides Pharma Science continues to strengthen its market position through strategic collaborations and a dedication to meeting the evolving needs of patients worldwide.
DitchCarbon Score
How does Strides Pharma Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Strides Pharma Science's score of 35 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Strides Pharma Science's reported carbon emissions
In 2025, Strides Pharma Science reported total global emissions of approximately 53,760,000 kg CO2e for Scope 1, 17,099,000 kg CO2e for Scope 2, and 47,827,000 kg CO2e for Scope 3. The combined total for Scope 1 and 2 emissions was about 22,475,000 kg CO2e. In India, the company disclosed Scope 1 emissions of approximately 5,332,000 kg CO2e and Scope 2 emissions of about 19,893,000 kg CO2e for the same year. Strides Pharma has set ambitious reduction targets, aiming for a 42% reduction in absolute Scope 1 and Scope 2 emissions by FY2030, compared to the base year FY2023. The company is also in the process of formulating a long-term decarbonisation strategy to contribute to the global Net Zero agenda, with a target timeframe extending to 2050 for both Scope 1 and Scope 2 emissions. The company is committed to achieving net-zero emissions, as indicated by its commitment status with the Science Based Targets initiative (SBTi). This commitment reflects Strides Pharma's proactive approach to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Scope 1 | 6,206,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 19,960,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Strides Pharma Science's Industry?
How Carbon Intensive is Strides Pharma Science's Location?
Strides Pharma Science's Scope 3 Categories Breakdown
Strides Pharma Science's Scope 3 emissions, which increased by 0% last year and increased by approximately 0% since 2024, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 68% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 44% of Scope 3 emissions.
Top Scope 3 Categories
Strides Pharma Science's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Strides Pharma Science has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
